Low-grade NMIBC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (NCT06995677) | Tyra Biosciences, Inc | 2025-06-27 |
Track Low-grade NMIBC automatically
Every clearance here is in the API, with alerts when new ones post.